Form 4: Xtant Medical Holdings CEO Sean E. Browne Reports Acquisition of Restricted Stock Units

Sean E. Browne, President and CEO of Xtant Medical Holdings, reports the acquisition of restricted stock units under the company's equity incentive plans.

Summary

• On April 3, 2024, Sean E. Browne, the President and CEO of Xtant Medical Holdings, Inc., acquired 731,632 shares of common stock.
• These shares are in the form of restricted stock units (RSUs) that will vest over four years.
• The vesting schedule is April 3, 2025, April 3, 2026, April 3, 2027, and April 3, 2028, with 182,908 shares vesting on each date.
• Vesting is contingent upon Browne's continued employment with Xtant Medical through each vesting date.
• Following the transaction, Browne beneficially owns 2,306,990 shares, including shares issuable upon vesting of RSUs granted under the 2023 and Amended and Restated 2018 Equity Incentive Plans.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the CEO's ability to drive long-term value. However, it doesn't provide any specific information about the company's current performance or future prospects.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value over the long term.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The vesting of the RSUs is contingent upon the CEO's continued employment, creating a potential risk if he were to leave the company before the vesting dates.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future outlook, but the equity incentive plan suggests a commitment to long-term growth and value creation.

Industry Context

Equity compensation is a common practice in the medical device industry to attract and retain top talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among publicly traded companies, including medical device companies like Medtronic, Stryker, and Johnson & Johnson.
• The vesting schedule of four years is also common, aligning with industry norms for executive compensation packages.
• The size of the grant relative to the CEO's existing holdings and the company's market capitalization would be a relevant benchmark for comparison.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the CEO's interests with those of shareholders, potentially leading to increased shareholder value over the long term.
• Employees: The equity incentive plan may also include grants to other employees, incentivizing them to contribute to the company's success.
• The document does not directly impact customers, suppliers, or creditors.

Key Dates